Apoptosis of monocytes and the influence on yield of monocyte-derived dendritic cells

被引:19
作者
Bohnenkamp, HR [1 ]
Burchell, JM
Taylor-Papadimitriou, J
Noll, T
机构
[1] Guys Hosp, Canc Res UK, Breast Canc Biol Grp, London SE1 9RT, England
[2] Res Ctr Julich GmbH, Inst Biotechnol, D-52428 Julich, Germany
关键词
monocytes; dendritic cells; apoptosis; annexin V; yield;
D O I
10.1016/j.jim.2004.08.010
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Monocyte-derived dendritic cells (DC) are currently under extensive evaluation as cell vaccines for cancer treatment. The requirement for large-scale cell products demands optimized and standardized protocols. However, the yield of DCs from inoculated monocytes is reported to be always lower than 50%. In this present study we investigated whether this cell loss was caused by the properties of the starting population of inoculated monocytes. CD14 cells were enriched by immunomagnetic-bead selection and analyzed for apoptosis by an annexin V/propidium iodide assay. We found that 37.8 +/- 11.1% (n=8) of freshly isolated monocytes from buffy coats of healthy donors underwent programmed cell death. Further analysis of the fate of apoptotic cells during differentiation suggested phagocytosis. Monocytes were differentiated with GM-CSF and interleukin-4 into a viable, non-apoptotic population of immature dendritic cells. Addition of tumor necrosis factor-alpha and prostaglandin E-2 resulted in fully matured dendritic cells, which were evaluated by phenotypic analysis and by allogeneic and MHC class-I-restricted T-cell responses. About 90.2 +/- 16.7% of the non-apoptotic monocyte population differentiated to viable matured dendritic cells. These results indicate that the yield of dendritic cells is mainly influenced by the percentage of apoptotic cells in the inoculum, and this has implications for DC generation in clinical applications. (C) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:67 / 80
页数:14
相关论文
共 44 条
[1]   DEVELOPMENT OF HIGH POTENCY UNIVERSAL DR-RESTRICTED HELPER EPITOPES BY MODIFICATION OF HIGH-AFFINITY DR-BLOCKING PEPTIDES [J].
ALEXANDER, J ;
SIDNEY, J ;
SOUTHWOOD, S ;
RUPPERT, J ;
OSEROFF, C ;
MAEWAL, A ;
SNOKE, K ;
SERRA, HM ;
KUBO, RT ;
SETTE, A ;
GREY, HM .
IMMUNITY, 1994, 1 (09) :751-761
[2]   PRIMARY CULTURES OF HUMAN BLOOD-BORNE MACROPHAGES GROWN ON HYDROPHOBIC TEFLON MEMBRANES [J].
ANDREESEN, R ;
PICHT, J ;
LOHR, GW .
JOURNAL OF IMMUNOLOGICAL METHODS, 1983, 56 (03) :295-304
[3]   Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories™ [J].
Berger, TG ;
Feuerstein, B ;
Strasser, E ;
Hirsch, U ;
Schreiner, D ;
Schuler, G ;
Schuler-Thurner, B .
JOURNAL OF IMMUNOLOGICAL METHODS, 2002, 268 (02) :131-140
[4]   EXPOSURE OF ENDOGENOUS PHOSPHATIDYLSERINE AT THE OUTER SURFACE OF STIMULATED PLATELETS IS REVERSED BY RESTORATION OF AMINOPHOSPHOLIPID TRANSLOCASE ACTIVITY [J].
BEVERS, EM ;
TILLY, RHJ ;
SENDEN, JMG ;
COMFURIUS, P ;
ZWAAL, RFA .
BIOCHEMISTRY, 1989, 28 (06) :2382-2387
[5]   Development of a standardized protocol for reproducible generation of matured monocyte-derived dendritic cells suitable for clinical application [J].
Bohnenkamp, HR ;
Noll, T .
CYTOTECHNOLOGY, 2003, 42 (03) :121-131
[6]   Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies [J].
Brossart, P ;
Heinrich, KS ;
Stuhler, G ;
Behnke, L ;
Reichardt, VL ;
Stevanovic, S ;
Muhm, A ;
Rammensee, HG ;
Kanz, L ;
Brugger, W .
BLOOD, 1999, 93 (12) :4309-4317
[7]   MACROPHAGE COLONY-STIMULATING FACTOR IS REQUIRED FOR HUMAN MONOCYTE SURVIVAL AND ACTS AS A COFACTOR FOR THEIR TERMINAL DIFFERENTIATION TO MACROPHAGES INVITRO [J].
BRUGGER, W ;
KREUTZ, M ;
ANDREESEN, R .
JOURNAL OF LEUKOCYTE BIOLOGY, 1991, 49 (05) :483-488
[8]   Generation of antigen-loaded dendritic cells in a serum-free medium using different cytokine combinations [J].
Büchler, T ;
Hajek, R ;
Bourkova, L ;
Kovarova, L ;
Musilova, R ;
Bulikova, A ;
Doubek, M ;
Svobodnik, A ;
Mareschova, I ;
Vanova, P ;
Tuzova, E ;
Vidlakova, P ;
Vorlicek, J ;
Penka, M .
VACCINE, 2003, 21 (9-10) :877-882
[9]  
Cornelissen M, 2002, APOPTOSIS, V7, P41
[10]   Optimizing preparation of normal dendritic cells and bcr-abl+ mature dendritic cells derived from immunomagnetically purified CD14+ cells [J].
Dietz, AB ;
Bulur, PA ;
Erickson, MR ;
Wettstein, PJ ;
Litzow, MR ;
Wyatt, WA ;
Dewald, GW ;
Tefferi, A ;
Pankratz, VS ;
Vuk-Pavlovic, S .
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH, 2000, 9 (01) :95-101